Antigen News and Research

RSS

New, rapid test detects ovarian cancer more accurately

The CA125 antigen, a plasma membrane glycoprotein found in the tissues of the female reproductive tract, is commonly used for the detection of ovarian cancer but works poorly on its own in identifying early stage cancers.

11 Sep 2020

New review explores the role of antibodies and T-cells towards an effective COVID vaccine

More than 100 companies have rushed into vaccine development against COVID-19 as the U.S. government pushes for a vaccine rollout at "warp speed" -- possibly by the end of the year -- but the bar set for an effective, long-lasting vaccine is far too low and may prove dangerous, according to Marc Hellerstein of the University of California, Berkeley.

11 Sep 2020

New antitumor vaccines control melanoma growth in preclinical models

Combining their expertise in protein engineering and synthetic DNA technology, scientists at The Wistar Institute successfully delivered nanoparticle antitumor vaccines that stimulated robust CD8 T cell immunity and controlled melanoma growth in preclinical models.

11 Sep 2020

Effective, simple, safe self-amplifying RNA vaccines

A recent review paper in the journal Current Opinion in Virology in September 2020 shows how a new generation of RNA vaccines called self-amplifying RNA vaccines are more potent than conventional mRNA vaccines and could hold the key to the global production of cost-effective potent COVID-19 vaccines.

11 Sep 2020

Study reviews recent insights into the pathogenesis of feline leukemia virus infection

Feline leukaemia virus (FeLV) is a gammaretrovirus that occurs worldwide in domestic cats, as well as small wild cats. It is associated with various serious, and sometimes fatal, diseases including anaemia, immunosuppression and certain cancers

10 Sep 2020

Pfizer, BioNTech COVID-19 vaccine candidate shows promise in preclinical study

Researchers in the United States and Germany have conducted a study demonstrating the preclinical efficacy of a new candidate vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent that causes coronavirus disease 2019 (COVID-19).

9 Sep 2020

Memory B cells indicate durable immunity in COVID-19

Now a new study by researchers at SUNY Upstate Medical University and published recently on the preprint server medRxiv in September 2020 shows that memory B cells are upregulated in convalescent COVID-19 patients, correlating with a better immune response and shorter symptom duration.

8 Sep 2020

Avacta to launch Affimer-based ELISA test for SARS-CoV-2 virus detection

Avacta Group plc, the developer of Affimer biotherapeutics and reagents, is pleased to announce that it will launch an ELISA laboratory test for the SARS-CoV-2 spike protein to support global research efforts into the coronavirus that causes COVID-19.

From Avacta Life Sciences Ltd. 8 Sep 2020

Antibody-mediated platelet death linked to COVID-19 severity

A new study by University of Tuebingen researchers shows the strong association between platelet apoptosis and the thrombotic manifestations that may underlie critical COVID-19 illness.

7 Sep 2020

Novel RNA vaccine from Arcturus Therapeutics protects mice against SARS-CoV-2

A new study published on the preprint server bioRxiv in September 2020 reports a novel RNA vaccine platform that shows robust protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in mice and performs much better than a conventional mRNA vaccine. This could allow single-dose immunization, allowing progress towards global vaccination.

6 Sep 2020

Antibody responses against seasonal common cold coronaviruses may protect against SARS-CoV-2

With the use of an accurate high throughput assay, researchers from the Weizmann Institute of Science and Magen David Adom Blood Services in Israel showed substantial inter-individual variability and antibody cross-reactivity against seasonal coronaviruses upon SARS-CoV-2 infection, with important implications for immune surveys and vaccines. The study is currently available on the medRxiv* preprint server.

6 Sep 2020

Spike-based priming leads to high neutralizing activity in animal models

A new report by researchers at the University of Melbourne and published on the preprint server bioRxiv in September 2020 reports on the use of a two-protein two-dose vaccine regimen and its immunogenicity in two animal models.

4 Sep 2020

Research compares T cell responses to SARS-CoV-2 and influenza

As the COVID-19 pandemic continues to grow, scientists are focusing on understanding how the host immune system responds to the virus in order to better shape public health responses and develop effective vaccines. A new study published on the preprint server medRxiv in September 2020 reports the T cell memory response to the SARS-CoV-2 spike protein, recombinant nucleocapsid protein, and other pooled peptides derived from convalescent patients.

3 Sep 2020

Improving COVID-19 diagnosis

News-Medical spoke to Yourgene health on their efforts during the COVID-19 pandemic, and how they developed a diagnostic test for COVID-19.

From Yourgene Health 3 Sep 2020

Bioengineering technique that boosts protein production could lead to effective COVID-19 vaccine

A bioengineering technique to boost production of specific proteins could be the basis of an effective vaccine against the novel coronavirus that causes COVID-19, new research suggests.

3 Sep 2020

Avacta enters into manufacturing agreement with Abingdon Health for rapid SARS-CoV-2 antigen test

Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has entered into an agreement with Abingdon Health for the manufacture of Avacta’s saliva-based rapid SARS-CoV-2 antigen test as part of its ongoing expansion of manufacturing capacity.

From Avacta Life Sciences Ltd. 3 Sep 2020

Promising new candidate 'virus-like particle' vaccine for COVID-19

Researchers in the UK and Taiwan have demonstrated the potential of a new candidate vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the virus responsible for the current coronavirus disease 2019 (COVID-19) pandemic.

1 Sep 2020

Spike ferritin nanoparticles show potential as SARS-CoV-2 vaccine

Now, a new study published on the preprint server bioRxiv* in August 2020 reports the induction of neutralizing antibodies in mice by a single dose of a ferritin nanoparticle-based vaccine containing the spike protein.

1 Sep 2020

Unique antibody profile differentiates people with non-celiac gluten sensitivity

A new study of the antibodies produced by people with gluten sensitivity may lead to a better way to detect the condition and treat it.

31 Aug 2020

A nanoscaffolding approach for rapid design of highly immunogenic SARS-CoV-2 vaccines

A research group from Slovenia, Switzerland, and Germany shows how nanoscaffolded assemblies may neutralize interaction between the SARS-CoV-2 spike protein and cell receptor, providing adequate protection in a surrogate infection assay and warranting the advance of such platforms in the pursuit for the effective vaccine.

31 Aug 2020

Antigen News and Research

New, rapid test detects ovarian cancer more accurately

New review explores the role of antibodies and T-cells towards an effective COVID vaccine

New antitumor vaccines control melanoma growth in preclinical models

Effective, simple, safe self-amplifying RNA vaccines

Study reviews recent insights into the pathogenesis of feline leukemia virus infection

Pfizer, BioNTech COVID-19 vaccine candidate shows promise in preclinical study

Memory B cells indicate durable immunity in COVID-19

Avacta to launch Affimer-based ELISA test for SARS-CoV-2 virus detection

Antibody-mediated platelet death linked to COVID-19 severity

Novel RNA vaccine from Arcturus Therapeutics protects mice against SARS-CoV-2

Antibody responses against seasonal common cold coronaviruses may protect against SARS-CoV-2

Spike-based priming leads to high neutralizing activity in animal models

Research compares T cell responses to SARS-CoV-2 and influenza

Improving COVID-19 diagnosis

Bioengineering technique that boosts protein production could lead to effective COVID-19 vaccine

Avacta enters into manufacturing agreement with Abingdon Health for rapid SARS-CoV-2 antigen test

Promising new candidate 'virus-like particle' vaccine for COVID-19

Spike ferritin nanoparticles show potential as SARS-CoV-2 vaccine

Unique antibody profile differentiates people with non-celiac gluten sensitivity

A nanoscaffolding approach for rapid design of highly immunogenic SARS-CoV-2 vaccines

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News